Pura Vida Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pura Vida Investments’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-106,629	Closed	-$1.22M	–	92
2022 Q4	$1.22M	Sell	106,629 -170,000	-61%	-$2.12M	0.06%	141
2022 Q3	$3.49M	Sell	276,629 -87,623	-24%	-$1.13M	0.2%	109
2022 Q2	$3.85M	Buy	+364,252	New	+$3.76M	0.22%	105
2021 Q1	–	Sell	-412,419	Closed	-$3.07M	–	219
2020 Q4	$3.07M	Sell	412,419 -309,500	-43%	-$1.6M	0.11%	123
2020 Q3	$2.48M	Buy	721,919 +285,419	+65%	+$1.22M	0.13%	114
2020 Q2	$2.08M	Buy	+436,500	New	+$1.74M	0.2%	86
2020 Q1	–	Sell	-2,179,950	Closed	-$7.52M	–	98
2019 Q4	$7.52M	Buy	+2,179,950	New	+$5.48M	0.66%	46
2018 Q4	–	Sell	-101,245	Closed	-$773K	–	82
2018 Q3	$773K	Buy	+101,245	New	+$680K	0.16%	93
2017 Q4	–	Sell	-150,000	Closed	-$786K	–	73
2017 Q3	$786K	Buy	150,000 +50,000	+50%	+$256K	0.23%	71
2017 Q2	$556K	Buy	+100,000	New	+$609K	0.22%	59

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Pura Vida Investments's BCRX Position: Q1 2023 in Review

Pura Vida Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 106,629 shares — an estimated $1.22M sold.

Pura Vida Investments first reported a position in BCRX in Q2 2017 and held it in 10 quarters. The position peaked at $7.52M in Q4 2019. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

Pura Vida Investments reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Pura Vida Investments sold 106,629 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $1.22M.
Pura Vida Investments first reported a position in BioCryst Pharmaceuticals in Q2 2017 and held it in 10 quarters.
Pura Vida Investments's BioCryst Pharmaceuticals position peaked at $7.52M in Q4 2019.
241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.